{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-045370","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.189914+00:00","generated_at":"2026-05-30T04:59:04.938094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis Q3 revenue $134M (-7% YoY); reaffirms 2024 P&L guidance; increases cash guidance to $2.2B","bullets":["Q3 total revenue $134M vs $144M YoY; commercial revenue $76M, R&D revenue $58M.","WAINUA royalty revenue $5M in Q3 ($10M YTD); SPINRAZA royalties $57M in Q3 ($152M YTD).","Olezarsen PDUFA Dec 19, 2024 for FCS; donidalorsen PDUFA Aug 21, 2025 for HAE.","Cash & investments $2.5B at Sep 30; raised ~$500M from 11.5M-share offering at $43.50.","Phase 3 ION582 for Angelman syndrome to begin H1 2025 after positive FDA end-of-Phase 2 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-045370","json":"https://secwatch.observer/filing/0001140361-24-045370.json","markdown":"https://secwatch.observer/filing/0001140361-24-045370.md","text":"https://secwatch.observer/filing/0001140361-24-045370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036124045370/0001140361-24-045370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036124045370/ef20038192_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:59:04.938094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}